Brimonidine is neuroprotective against glutamate-induced neurotoxicity, oxidative stress, and hypoxia in purified rat retinal ganglion cells - PubMed (original) (raw)
Brimonidine is neuroprotective against glutamate-induced neurotoxicity, oxidative stress, and hypoxia in purified rat retinal ganglion cells
Kelvin Yoon Chiang Lee et al. Mol Vis. 2010.
Abstract
Purpose: To investigate the neuroprotective effect of alpha2-adrenergic agonist brimonidine in the presence of glutamate-induced neurotoxicity, oxidative stress, and hypoxia on in vitro cultures of purified rat retinal ganglion cells (RGCs).
Methods: Purified RGC cultures were obtained from retinas of 6-8-day old Wistar rats, following a two-step immunopanning procedure. After 72 h of cultivation, the neuroprotective effect of brimonidine (0.01 microM, 0.1 microM, and 1 microM) was investigated by culturing the RGCs under glutamate, oxidative, and hypoxic stress for a further 72 h, 24 h, and 12 h, respectively. Glutamate neurotoxicity was induced by adding glutamate (25 microM), while oxidative stress was induced by substituting the culture medium with B27 supplement without antioxidants, and hypoxia was induced by cultivation in a controlled-atmosphere incubator with oxygen levels 5% of the normal partial pressure. The RGC viability under each stress condition normalized to that under normal condition was evaluated as live cell percentage based on a total of 7-8 full repeated experiments.
Results: The cell survival percentages of cultures exposed to glutamate, oxidative, and hypoxic stress were 58.2%, 59.3%, and 53.2%, respectively. Brimonidine dose dependently increased RGC survival in the presence of glutamate (80.6% at 1 microM), oxidative (79.8% at 1 microM), and hypoxic (72.3 and 77.4% at 0.1 and 1 microM, respectively) stress. In the presence of alpha2-adrenergic antagonist yohimbine (10 microM), brimonidine (1 microM) showed no protective effects on RGC viability.
Conclusions: At a concentration of 0.1 microM or higher, brimonidine increased survival of purified rat RGCs in the presence of glutamate neurotoxicity, oxidative stress, and hypoxia. The neuroprotective effect of brimonidine is mediated via alpha2-adrenergic receptors at the RGC level.
Figures
Figure 1
Retinal ganglion cell viability of seven experiments under (A) glutamate-induced neurotoxicity, (B) oxidative stress, and (C) hypoxic stress, with increasing concentrations of brimonidine. Brimonidine at a concentration of 1 μM significantly increased retinal ganglion cell (RGC) viability in all three stresses. Abbreviations: (-) represents control RGC cultures without glutamate; (+) represents control RGC cultures with glutamate, AO(+)represents medium with anti-oxidant; AO(-) represents medium without anti-oxidant, * represents p<0.01. n=7. Error bar indicates SD.
Figure 2
Retinal ganglion cell viability of eight experiments under (A) glutamate-induced neurotoxicity, (B) oxidative stress, and (C) hypoxic stress. The neuroprotective effect of 1 μM brimonidine was reproduced in all three stresses. The effect of brimonidine on the increase in retinal ganglion cell (RGC) viability was blocked by the α2-adrenergic antagonist yohimbine in all three stresses. Abbreviations: (+) represents control RGC cultures with glutamate; AO(+) represents medium with anti-oxidant; AO(-) represents medium without anti-oxidant; B represents RGC cultures with brimonidine added; B+Y represents RGC cultures with brimonidine and yohimbine added; Y represents RGC cultures with yohimbine added; *, p<0.001; n=7. Error bar indicates SD.
Similar articles
- Neuroprotective effect of astaxanthin against rat retinal ganglion cell death under various stresses that induce apoptosis and necrosis.
Yamagishi R, Aihara M. Yamagishi R, et al. Mol Vis. 2014 Dec 31;20:1796-805. eCollection 2014. Mol Vis. 2014. PMID: 25593507 Free PMC article. - Neuroprotective effects of prostaglandin analogues on retinal ganglion cell death independent of intraocular pressure reduction.
Yamagishi R, Aihara M, Araie M. Yamagishi R, et al. Exp Eye Res. 2011 Sep;93(3):265-70. doi: 10.1016/j.exer.2011.06.022. Epub 2011 Jul 26. Exp Eye Res. 2011. PMID: 21791206 - Neuroprotective effects of flavonoids on hypoxia-, glutamate-, and oxidative stress-induced retinal ganglion cell death.
Nakayama M, Aihara M, Chen YN, Araie M, Tomita-Yokotani K, Iwashina T. Nakayama M, et al. Mol Vis. 2011;17:1784-93. Epub 2011 Jul 2. Mol Vis. 2011. PMID: 21753864 Free PMC article. - Comparison of the neuroprotective effects of adrenoceptor drugs in retinal cell culture and intact retina.
Baptiste DC, Hartwick AT, Jollimore CA, Baldridge WH, Chauhan BC, Tremblay F, Kelly ME. Baptiste DC, et al. Invest Ophthalmol Vis Sci. 2002 Aug;43(8):2666-76. Invest Ophthalmol Vis Sci. 2002. PMID: 12147601 - Role of alpha-2 agonists in neuroprotection.
Wheeler L, WoldeMussie E, Lai R. Wheeler L, et al. Surv Ophthalmol. 2003 Apr;48 Suppl 1:S47-51. doi: 10.1016/s0039-6257(03)00004-3. Surv Ophthalmol. 2003. PMID: 12852434 Review.
Cited by
- Advances in Neuroprotection in Glaucoma: Pharmacological Strategies and Emerging Technologies.
Wang LH, Huang CH, Lin IC. Wang LH, et al. Pharmaceuticals (Basel). 2024 Sep 25;17(10):1261. doi: 10.3390/ph17101261. Pharmaceuticals (Basel). 2024. PMID: 39458902 Free PMC article. Review. - A combination of topical and systemic administration of brimonidine is neuroprotective in the murine optic nerve crush model.
Maciulaitiene R, Kalesnykas G, Pauza DH, Januleviciene I. Maciulaitiene R, et al. PLoS One. 2024 Aug 8;19(8):e0308671. doi: 10.1371/journal.pone.0308671. eCollection 2024. PLoS One. 2024. PMID: 39116180 Free PMC article. - Effect of brimonidine on vascular density and imagej-derived flow index of optic nerve head and macula in primary open angle glaucoma.
Ameen Ismail A, Sadek S, Hatata R, Kamal M. Ameen Ismail A, et al. Int Ophthalmol. 2024 Jul 4;44(1):311. doi: 10.1007/s10792-024-03221-7. Int Ophthalmol. 2024. PMID: 38963456 - Exploring Neuroprotective Effects of Topical Brimonidine in Experimental Diabetic Retinopathy.
Jung KI, Kim JH, Han JS, Park CK. Jung KI, et al. In Vivo. 2024 Jul-Aug;38(4):1609-1620. doi: 10.21873/invivo.13611. In Vivo. 2024. PMID: 38936912 Free PMC article. - Brain-Derived Neurotrophic Factor-Mediated Neuroprotection in Glaucoma: A Review of Current State of the Art.
Lambuk L, Mohd Lazaldin MA, Ahmad S, Iezhitsa I, Agarwal R, Uskoković V, Mohamud R. Lambuk L, et al. Front Pharmacol. 2022 May 20;13:875662. doi: 10.3389/fphar.2022.875662. eCollection 2022. Front Pharmacol. 2022. PMID: 35668928 Free PMC article. Review.
References
- Castagne V, Gautschi M, Lefevre K, Posada A, Clarke PG. Relationships between neuronal death and the cellular redox status. Focus on the developing nervous system. Prog Neurobiol. 1999;59:397–423. - PubMed
- Flammer J, Pache M, Resink T. Vasospasm, its role in the pathogenesis of diseases with particular reference to the eye. Prog Retin Eye Res. 2001;20:319–49. - PubMed
- Levkovitch-Verbin H, Harris-Cerruti C, Groner Y, Wheeler LA, Schwartz M, Yoles E. RGC death in mice after optic nerve crush injury: oxidative stress and neuroprotection. Invest Ophthalmol Vis Sci. 2000;41:4169–74. - PubMed
- Lipton SA. Retinal ganglion cells, glaucoma and neuroprotection. Prog Brain Res. 2001;131:712–8. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources